WO2003011209A2 - Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes - Google Patents
Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes Download PDFInfo
- Publication number
- WO2003011209A2 WO2003011209A2 PCT/IL2002/000628 IL0200628W WO03011209A2 WO 2003011209 A2 WO2003011209 A2 WO 2003011209A2 IL 0200628 W IL0200628 W IL 0200628W WO 03011209 A2 WO03011209 A2 WO 03011209A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beads
- hepatocyte
- hepatocytes
- viral
- hbv
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Definitions
- the present invention relates to methods of sensitizing hepatocyte cell cultures to hepatitis infection.
- the present invention further relates to beads coated with HBV or HCV derived ligands and methods of using same to model viral infection or deliver substances into hepatocytes.
- hepatitis B virus HBV
- HCV hepatitis C virus
- HBV HBV in the United States; the estimated total number of carriers in the world is greater than 200 million.
- HBV is implicated in both acute and chronic hepatitis. The disease is endemic in Asia and is increasing in prevalence in the U.S. and Europe. Chronic liver disease, resulting in significant morbidity and increased mortality, is a complication of infection in 1-10% of mfected individuals. HBV infection is also correlated with the development of primary liver cancer.
- HCV was recently shown to be the major causative agent of parenterally transmitted non-A, non-B hepatitis. It is estimated that 0.5-1% of the world population is infected with HCV, and in some developing countries the prevalence rate is up to 40%. Moreover, 40-60% of newly infected patients develop persistent HCV infections and are at risk of developing acute, fulminant hepatitis and various chronic liver diseases (including cirrhosis, chronic active hepatitis and in some cases hepatocellular carcinoma). Although HBV and HCV have been identified and characterized, the development of new anti-viral strategies has been greatly hampered by the lack of convenient systems for infection and propagation in cultured hepatocytes.
- Hepatitis Virus In Vitro Hepadnaviruses which include HBV, exhibit very narrow host and tissue specificity. Efficient infection by HBV is well documented for only humans and chimpanzees and, in cell culture, for primary hepatocytes from these hosts.
- biological assays for HBV have been limited to the experimental inoculation of chimpanzees, which are expensive and limited in numbers.
- Generic animal models exist, such as the woodchuck-woodchuck hepatitis B virus (WHV) and the duck-duck hepatitis B virus (DHBV) systems, but cannot support human HBV infection.
- HBV woodchuck-woodchuck hepatitis B virus
- DHBV duck-duck hepatitis B virus
- Some rodent-based surrogate systems are available, although they are not infectable and require immunosuppression to prevent rejection of the human liver xenotransplants. Thus, little is known about the process of HBV attachment and infection of hepatocytes.
- H uman p rimary h epatocytes are variably susceptible to infection and for only a short period after culturing (Mabit H et al J Hepatol 1996;24:403-412), but these systems are not practical because they are short-lived, require primary explanted liver from surgical biopsies, and are inconsistently susceptible.
- Polyethylene glycol or DMSO to the culture medium improved the interaction between the cells and the virus.
- DMSO Polyethylene glycol or DMSO to the culture medium.
- higher rates of infectivity Gripon P et al J Virol 1988;62:4136-43 and Gripon P et al Virol 1993;192:534-40
- longer-term episomal replication of the virus Rumin S et al J Viral Hepat 1996;3:227-38
- DMSO treatment has also been used to improve DHBV infectivity and expression in primary duck hepatocytes (Galle PR et al Hepatology 1989;10:459-65), and it has been suggested that this solution mediator acts by maintaining the differentiated state of the cultured hepatocytes.
- the methylation inhibitor 5-Aza-2 Deoxycytidine which has been used to induce lytic viral growth of Human Herpesvirus 8 in BCB cells (U.S. Pat No.
- virus surface proteins One of the essential functions of virus surface proteins is the recognition of specific receptors on target cell membranes.
- the specific attachment of viruses to cells is the essential first step in virus entry into cells.
- the receptor specificity encoded in restricted regions of the virus surface structure can determine the virus host range, tissue tropism and pathogenesis.
- host cell receptors specific for different viruses have been identified as receptors for discrete physiologically important ligands. Therefore, viral binding to the host cell constitutes an aspect of virus-cell interactions critical to investigation, diagnostics and prevention of infection.
- the HBV viral envelope is composed of a cellular originated membrane in which several virus coded surface proteins are anchored.
- HBsAgs small HBsAgs (p24 and gp 28), the middle HBsAgs (gp33 and gp 36) and the large HBsAgs (p39 and gp 42).
- the large HBsAg of both avian and the mammalian hepadnaviruses is believed to play a major role in mediating virus attachment and entry to hepatocytes: indeed, antibodies against HBsAg are protective against HBV infection and the use of purified and recombinant HBsAg for diagnostic, prophylactic, vaccination and therapeutic purposes has been disclosed in U.S. Pat. Nos.
- Hepadnaviruses replicate almost exclusively in the liver. This liver tropism is believed to be determined, at least in part, by hepatocyte viral specific receptors and co-receptors.
- the gpl80 protein was recently identified as the putative duck hepatitis B virus (DHBV) receptor in duck hepatocytes.
- DHBV duck hepatitis B virus
- Suspected human HBV liver specific receptors include annexin V (Hertogs K et al Virology 1993;197:549-57), apolipoprotein H (Mehdi H et al J of Virol 1994;68:2415-24) and asialoglycoprotein (Treichel V et al, J Gen Virol 1994;75:3021-29).
- HCV envelope proteins critical to viral attachment and infection of hepatocytes have also been identified, among these the HCV El, E2 and E1/E2 envelope proteins (Spaete RR et al, Virology 1 992;188:819-30). N ative and recombinant El, E2 and E1/E2 proteins have also been proposed for use in vaccination, and in diagnostic and therapeutic applications (see U.S. Pat. Nos.
- Ligand-Mediated Targeting of Hepatocytes The specificity of many interactions of the cell surface with elements present i n the cellular environment, such as extracellular matrix, neighboring cells, macromolecules or microorganisms, provides the basis for many powerful investigative, diagnostic and therapeutic tools. Where a specific ligand has been identified, it can be used for detecting and isolating receptor-bearing cells and their receptors, defining and visualizing ligand-mediated processes, demonstrating anti-ligand immune activity, screening potential agonist/antagonist activities, and targeting of substances to specific cell populations.
- Neurath et al, and others have disclosed the use of solid-phase immobilized HBsAg or anti-HBsAg antibodies, bound to agarose or polystyrene beads, for immunoassay, detection of anti-HBV antibodies, purification of viral proteins and their antibodies (U.S. Pat. Nos. 5,798,206; 5,620,844; 5,565,548 to Neurath et al; Valinger Z Vaccine 1990;8:585-89).
- liver specific ligands such as galactose and lactose (Cho CS et al, Biomaterials 2001;22:45-51, and van der Sluijs P et al Hepatology, 1986;6:723-28) and asialoglycoproteins (Watanabe Y et al J Biomat Sci Polym Ed 2000;11 :833-48 and Martinez-Fong D et al, Hepatology 1994;20:1602-08) have been used to deliver bound substances to hepatocytes in vivo and in vitro. Phagocytosis and endocytosis of microparticles coated with, or bearing specific ligands has also been demonstrated.
- Lymphocytes phagocytized CD8 immunobeads during magnetic sorting (Burkhardt O and Merker HJ Ann Anat 2002;184:55-60) and hepatocytes take up polybutylcyanoacrylate beads in vivo (Zhang ZR and He Q World Gastroent 1999;5:330-33).
- Defective hepatitis B viruses or viral antigens having strong affinity and avidity for hepatocytes, have also been proposed as ligands for gene therapy and drug delivery (Wang L et al, Virus Res 2002;85: 187-97; Wu J et al Front Biosci 2002;7:d717-25; and Protzer U et al PNAS USA 1999;96: 10818-823; recently reviewed by D Ganem, PNAS USA 1999;96:11696-97).
- De Bruin WC et al used small HBsAg-bound 10 nm gold particles to investigate the role of endonexin II in virus attachment (de Brain WC et al J Gen Virol 1995;76:1047-50).
- a method of obtaining cultured hepatocytes susceptible to viral infection the method effected by exposing the cultured hepatocytes to 5-Aza-2
- the viral infection is an HBV or an HCV infection.
- a method of quantifying binding between a ligand and a hepatocyte the method effected by contacting the hepatocyte with beads coated with the ligand and determining the amount of said beads bound to, or present in the hepatocyte to thereby quantify binding between the ligand and the hepatocyte.
- a method of delivering a substance into a hepatocyte the method effected by contacting the hepatocyte with a bead coated with a ligand capable of binding the hepatocyte; and the substance, thereby introducing the substance into the hepatocyte.
- a method of identifying a substance capable of modifying viral infection in hepatocytes the method effected by contacting the hepatocytes with beads coated with a viral ligand capable of binding the hepatocytes, wherein said contacting is performed in a presence of the substance; and determining the amount of said beads bound to, or present in the hepatocytes to thereby determine the ability of the substance to modify viral infection of the hepatocytes.
- the solution mediator is DMSO.
- the hepatocytes are HepG2 cells.
- the hepatocytes are human hepatocytes. According to yet further features in the described preferred embodiments the hepatocyte is a cultured hepatocyte.
- the hepatocyte is a cultured hepatocyte sensitized by contacting the hepatocyte with 5-Aza-2 Deoxycytidine and a solution mediator, to thereby obtain a sensitized hepatocyte.
- the ligand is a viral protein.
- the viral protein is HBsAg or a portion thereof.
- quantifying the beads is performed using a method of detection selected from the group consisting of microscopy, radioactivity, fluorescence, magnetic polarity, color detection and immuno-affinity.
- a method of detection selected from the group consisting of microscopy, radioactivity, fluorescence, magnetic polarity, color detection and immuno-affinity.
- contacting the hepatocyte is effected in a manner suitable for inducing endocytosis of the bead.
- contacting the beads is performed in vitro or in vivo.
- a composition-of-matter comprising a bead coated with a hepatitis viral protein selected from the group consisting of HBV-HBsAg or a portion thereof and HCV E2 or a portion thereof; and a bioactive substance, wherein a size and/or shape of said bead is selected suitable for undergoing endocytosis.
- a pharmaceutical composition comprising the composition-of-matter described hereinabove and a pharmaceutically acceptable carrier.
- the viral protein is a synthetic peptide.
- the ligand is a synthetic peptide comprising the amino acid sequence set forth in
- the beads are selected from the group consisting of polystyrene beads, dextran beads, glass beads and metal beads.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing novel methods for sensitizing cultured hepatocytes to hepatitis viral infection, beads c oated with HBV and HCV derived ligands, and an accurate and reliable method of directly quantitating hepatitis virus-hepatocyte binding and interaction, which can be used for development of diagnostic and therapeutic tools directed at virus-host cell recognition and interaction.
- FIGs. 1A-1D depict the infection of 5-Aza-2 Deoxycytidine- and DMSO-treated HepG2 cells by HBV.
- Figure 1A is a series of confocal micrographs demonstrating the immunofluorescent detection of HBV antigens HBcAg (red, Rhodamine Red-X conjugated antibodies) and HBsAg (green, FITC-conjugated antibodies) i n D MSO-treated ( left panels) but not untreated (right panels) HepG2 cells, following incubation with HBV positive human serum. Yellow color (Merge) represents detection of colocalization of the viral HBcAg and HBsAg antigens in infected HepG2 cells.
- Figure IB is a PAGE separation of PCR amplification products, demonstrating the efficient infection of DMSO-treated HepG2 cells by human HBV positive serum (lane 2).
- Virions contained only relaxed circular HBV DNA (RC-DNA) (lane 1)
- DMSO-treated cells contained both relaxed circular (RC-) and covalently closed circular (ccc- DNA) viral DNA (lane 2), while no viral DNA was detected in the untreated HepG2 cells (lane 3).
- Equal amounts of DNA were used for both treated and untreated controls (AML-2, lane 1 and 2).
- Figure 1C is a Southern blot analysis of total and extrachromosomal DNA demonstrating the presence of HBV replicative forms i n D MSO-treated H epG2 c ells incubated with human HBV positive serum.
- Lane 1 shows the migration of Mol. Wt. Markers.
- Lanes 2-11 show the presence of relaxed circular (RC), covalently closed circular (ccc) and single-strand (SS) viral DNA in total DNA [lanes 5-7, 5-14 days post infection (dpi), respectively] and extrachromosomal DNA (lane 11) from DMSO-treated HepG2 cells, indicating HBV infection.
- RC relaxed circular
- ccc covalently closed circular
- SS single-strand
- Figure ID is a series of confocal micrographs demonstrating the high-efficiency HBV infection of HepG2 cells pretreated with 5-Aza-2 Deoxycytidine and DMSO. Note the immunofluorescent detection of HBV antigens HBcAg (Core, green, FITC-conjugated antibodies) and HBsAg (red, Rhodamine Red-X conjugated antibodies) in 5-Aza-DC and DMSO-treated (TC-HBV and Serum HBV column) but not untreated (Control, center column) HepG2 cells, following incubation with HBV positive human serum (Serum HBV, right column) or pure concentrated virions (TC-HBV).
- HBV antigens HBcAg Core, green, FITC-conjugated antibodies
- HBsAg red, Rhodamine Red-X conjugated antibodies
- the cellular protein Cadherin was detected equally well in all cells (Cad, blue, Cy5 conjugated antibodies). Note the infection and coexpression (yellow:Merge) of the viral HBcAg and HBsAg antigens in 100% the pretreated (TC HBV, Serum HBV) but none of the untreated (Control) cells.
- FIGs. 2A-2C depict the expression, characterization and secretion of recombinant HBV sub-viral particles (SVPs) in stably transfected CHO cells.
- Figure 2A is a graphic representation of CsCl fractionation of sub-viral particles (SVPs) from CHO cells transfected with the HBV DNA (plasmid AL26). Purified particles were fractionated on CsCl gradient and the resulting fractions were assayed for HBsAg by radioimmunoassay using I labeled anti HBsAg antibodies.
- HBsAg SVPs density was calculated to be 1.22 gr/ml, characteristic of the 22nm sphere HBsAg SVPs.
- the insert shows 22nm particles that were negative stained by Uranyl Acetate followed by Transmission Electron microscopy.
- Figure 2B shows a SDS PAGE and immunoblot analysis of the recombinant HBsAg, demonstrating the presence of all three HBsAg components.
- the composition of the various surface proteins was demonstrated by 35 SMet labeling on SDS PAGE (lane 35 S) and by western analysis with the specific antibodies for native preSl (MA 18/7)(lane ⁇ Sl), preS2 (MA Q19/10)(lane S2) and with polyclonal anti S antibodies (lane ⁇ S).
- FIG. 2C is a schematic representation of the viral HBsAg proteins S (p24), M (p33) and L (p43), with their corresponding antibody epitopes.
- the grey boxes represent the transmembrane region.
- FIGs. 3A-3D are a micrographic demonstration of enhanced binding of SVP-beads on DMSO-treated HepG2 cells.
- Figures 3A and 3C are light micrographs (66X magnification) showing the binding of recombinant HBsAg component- conjugated 6 micron beads to untreated ( Figure 3 A) and DMSO- treated ( Figure 3C) HepG2 cells. Control beads are conjugated with BSA (BSA).
- BSA BSA
- FIGs. 4A-4H is a series of electron micrographs demonstrating DMSO- enhanced attachment to and endocytosis of recombinant SVP-conjugated beads by HepG2 cells.
- Figures 4A-4D are transmission electron micrographs showing the late stages (4A, 4B and 4D) and completion (4C) of engulfment of recombinant SVP-coated 6 micron beads by DMSO-treated HepG2 cells.
- Figure 4B is a higher magnification (1 micron bar equals 17 mm) of Figure 4A (1 micron bar equals 5 mm).
- Figures 4E-4H are scanning electron micrographs depicting efficient endocytosis of recombinant SVP-coated 6 micron beads by DMSO-treated HepG2 cells (4F), compared with the poor endocytosis by untreated (4E) cells.
- Various stages of beads internalization are demonstrated (4G and 4H), indicating tight association of the beads with the cell surface;
- FIGs. 5A and 5B are a graphic representation demonstrating DMSO- enhanced binding of the recombinant SVP protein, preSl region and 21-47 epitope of the HBsAg by HepG2 cells.
- 6 micron beads conjugated with one of the following; BSA, SVPs, recombinant preSl or synthetic peptide encompassing the amino acids 21-47 of preSl were incubated with DMSO- treated ( Figure 5A) or untreated ( Figure 5B) HepG2 cells. Numbers represent the percentage of cells, out of the total population, binding more than 4 beads per cell. Bars indicate standard deviation. Note the greater than 50 fold increase in binding to DMSO-treated cells;
- FIGs. 6A-6D depict the fine mapping of the preSl attachment sequence to the QLDPAF motif.
- Figure 6A is an amino acid sequence comparison showing the wild type (WT) QLDPAF sequence, and a recombinant mutant, scrambled (mutant pre SI) sequence.
- Figure 6B is a immunoblot showing the detection of His-tagged wild type recombinant pre Sl(WT) but not the scrambled recombinant mutant pre SI (mut) protein by anti preSl (MA 18/7) antibody (upper panel). Anti-6His antibody detected both wild type and scrambled mutant proteins equally well (bottom panel).
- Figure 6C is a graphic representation of the effect of scrambled QLDPAF motif on preSl protein binding to HepG2 cells.
- FIG. 6 6 micron beads coated with wild type (WT) or mutant scrambled (mut) recombinant preSl protein were incubated with DMSO-treated HepG2 cells, and scored for binding micrographically, as in Figure 3 (% of cell with greater than 4 beads per cell). Note the significant loss of attachment ability of mutant protein-conjugated beads. Preincubation of the cells with BSA (BSA) or mutant scrambled preSl protein (mut) resulted in no significant reduction of wild type binding (competition).
- Figure 6D is an amino acid sequence comparison demonstrating the widespread distribution of the QLDFAP motif throughout diverse species. Database search revealed the presence of QLDFAP-like sequences in another HBV protein (HBV pX), and in many viral and bacterial (panel A) and eukaryotic (panel B) adhesion, attachment and fusion molecules;
- FIGs. 7 A and 7B demonstrate the binding by DMSO and 5 -Aza-2-D- treated HepG2 cells of small sub-viral particles (sSVP) containing a non-preSl and non-preS2 attachment region.
- sSVP small sub-viral particles
- Recombinant sSVPs were produced by transfection of HEK 293 cells with the pMH8 plasmid.
- Figure 7A is Western blot with polyclonal anti HBsAg ( ⁇ S) and monoclonal anti preSl (MA 18/7) antibodies comparing the composition of the various HBsAgs in sSVPs and recombinant SVPs.
- the various HBsAgs L, M and S are indicated.
- Figure 7B is a graphic representation of the binding of sSVP and SVP- coated beads to HepG2 cells. 6 micron b eads coated with SVP (SVP) or sSVP (sSVP) recombinant protein were incubated with DMSO (+) or untreated (-) HepG2 cells, and scored for binding micrographically, as in Figure 3 (% of cells with greater than 4 beads per cell). Note the retention of significant attachment ability of sSVP protein-conjugated beads, despite their lacking the preSl and preS2 attachment regions. Also note that no significant binding was recorded with untreated (-) cells;
- FIG. 8 i s a g raphic d emonstration o f i nhibition o f b inding t o H ep G 2 cells, using pre SI, SVP and sSVP- coated beads.
- Figure 8A shows the effects of pre-binding incubation of the HepG2 cells with viral pre SI protein: complete inhibition of binding of pre Sl-coated beads (left panel, pre SI), and partial inhibition of binding of SVP-coated beads (middle panel, pre SI) and sSVP- coated (right panel, pre SI). Controls are pre-incubated with BSA (BSA), and results expressed as percentage of cells binding greater than 4 beads per cell.
- BSA BSA
- Figure 8B shows the effects of incubation with anti pre SI antibody MA 18/7 on Hep G2 binding of pre SI- and SVP- conjugated beads. Note the complete inhibition of binding of pre Sl-coated beads (left panel) by the antibody (left panel, MA 18/7), and the low but significant p ortion o fb inding o f S VP-coated b eads ( right p anel) unaffected by the antibody (right panel, MA 18/7);
- FIG. 9 is a micrographic demonstration of enhanced binding of HCV E2-beads on DMSO-treated HepG2 cells.
- Figures 9A and 9B are light micrographs (66X magnification) showing the efficient binding of baculovirus- prepared HCV E2-conjugated 6 micron beads to DMSO-treated ( Figure 9B) but not untreated ( Figure 9 A) HepG2 cells.
- the present invention is of novel methods of enhancing hepatitis viral infection of cultured hepatocytes. Specifically, the present invention can be used to obtain cultured human hepatocytes susceptible to HBV and HCV infection in vitro, for diagnostic and research applications. In addition, the present invention is also of bead compositions which can be used for identifying and screening substances modifying viral infection of hepatocytes, quantifying ligand binding to hepatocytes and for targeted delivery of bioactive substances to hepatocytes.
- hepatitis B and C virus attachment and infection is hampered by the fact that established human hepatocyte cell lines that express hepatocyte markers such as Hep G2 and Huh7 are refractive to infection. Since stable transformation of hepatocyte cell lines with the viral genome results in productive infection, hepatitis-transfected hepatocyte lines such as HepG2.21.5 (Gelbe D et al Intervirology 2001;44:370-78; Suri D et al J Hepat 2001 ;31 :790- 97; Weiss L et al Virology 1996;216:214-18) have become the standard for study of viral gene expression and anti-viral therapeutics. However, transfected cell lines cannot provide a model for the study of early events in viral infection such as mechanisms of viral attachment and introduction into the hepatocyte, and generally have a very low production rate.
- Human primary hepatocytes may be susceptible to hepatitis infection, but for only a short period after culturing (Mabit H et al J Hepatol 1996;24:403-
- Exposure of primary hepatocytes to DMSO can enhance the susceptibility of these cultures to infection with HBV (Gripon P et al Virol 1993;192:534-40; Rumin S et al J Viral Hepat 1996;3:227-38) and HCV (Rumin S et al J Gen Virol 1999;80:3007-3018; Intnl Pat. Applic. No. EP 0972828 Al to Rumin S et al).
- the method of the present invention can be used to develop hepatocyte culture systems for viral infection with, for example HBV and HCV, enabling investigation of primary hepatocyte-virus interaction and the screening of drags, such as anti-viral prophylactic agents.
- the present invention overcomes the limitations of restricted longevity, availability and variability inherent in primary hepatocyte culture, and the poor applicability of transfected hepatocyte cultures to investigation of hepatocyte-virus interactions.
- a method of obtaining cultured hepatocytes susceptible to viral infection The method is effected by exposing the cultured hepatocytes to 5-Aza-2
- solution mediator refers to a substance which improves the interaction of molecules such as proteins in a solution, with a solvent, resulting in enhanced solubility of the molecules.
- solution mediators are dimethylsulfoxide (DMSO), methyl sulfonyl methane
- cultured hepatocytes refers to hepatic or hepatic-derived cells which can be maintained in vitro under appropriate conditions (e.g. suitable medium, temperature, C0 2 saturation) preferably in a proliferative state. It will be appreciated that “cultured hepatocytes” are distinct from “primary hepatocyte cultures”, which are derived from tissue removed from live hosts, and cannot be induced to proliferate. Examples of such cultured hepatocytes are, for example, established human hepatoma cell lines such as Hep G2 and Huh7.
- the phrase "susceptible to viral infection" when used in context with a cultured hepatocyte refers to the ability of the hepatocyte to display signs of viral replication and/or expression of viral genes following exposure to virus particles, attachment, and internalization of virus particles.
- the solution mediator is DMSO, which is utilized in final concentration of 0.1 -5.0%
- V/V preferably 1.0-2.0%, most preferably 2.0%, along with the 5-Aza-2
- Deoxycytidine which is utilized at a final concentration of 10-200 mM, preferably 100 mM.
- the method for obtaining cultured hepatocytes susceptible to HBV and HCV infection of the present invention can be used to establish viable cultures of viral infected human hepatocytes, devoid of the inconsistency and poor availability of primary human hepatocyte culture.
- cultured hepatocytes are human hepatocytes. More preferably, the human cultured hepatocytes are Hep G2 cells.
- the viral infection of the method of the present invention is a human hepatotropic virus infection such as HBV or HCV.
- the cultured human hepatocytes susceptible to viral infection may also be used as a powerful screening tool for evaluating the anti- viral effectiveness of a compound, e.g., a drug or an antibody to be administered to a patient.
- a compound e.g., a drug or an antibody to be administered to a patient.
- Such an in vitro assay can be effected by providing a sample of susceptible hepatocytes; contacting the sample with virus and the compound to be tested, (e.g., for at least 15 minutes); and measuring parameters of viral infection, such as viral protein expression and DNA replication in the sample.
- Some compounds may require contacting the hepatocytes for longer than 15 minutes, e.g., 1 hour, 3 hours, 24 hours, or up to several days, in order to determine the effect of the compound on the viral infection of the hepatocytes.
- a decrease in, for example, viral attachment and/or viral replication in the hepatocytes in the presence of the test compound compared to that in the absence of the same compound indicates that the compound is likely to be effective in preventing infection in vivo.
- Such a screening assay is adaptable to automated high throughput technology employing large numbers and samples of cell cultures (for a review of high throughput screening techniques, see Kenny, BA et al Prog in Drug Res 1998;51).
- the infectiveness of various strains of virus in human hepatocytes may be assessed in a similar screening assay, wherein viral infection of susceptible cells is compared between strains having previously demonstrated, and those of undetermined, infectivity.
- a method of quantifying binding between a ligand and a hepatocyte is effected by contacting the hepatocyte with beads coated with the ligand and determining the amount of the beads bound to, or present in the hepatocyte, thereby quantifying binding between the ligand and the hepatocyte.
- the hepatocyte culture utilized by this aspect of the present invention is presensitized to infection as described hereinabove.
- binding refers to a specific affinity-based interaction between two or more molecular entities, resulting in attraction and varying degrees of physical association.
- the binding may be of varying strengths, typically defined by the strength of solvent washings which the bonded entities can withstand.
- ligand refers to a molecule which is recognized by, and has affinity for, another molecule or molecular s nestture, typically termed a "receptor".
- receptor a molecule which is recognized by, and has affinity for, another molecule or molecular s nestture, typically termed a "receptor”.
- the interaction between the ligand- receptor pair is of varying degrees of specificity, occurring at the surface o f cells or membranes, and initiating specific biological processes such as signal transduction or internalization of ligands.
- beads refers to any one of microspherical solid substrates suitable for conjugation with a putative ligand, having shape and dimensions affording specific interaction and binding between the ligand and a ligand-recognition entity on the surface of a hepatocyte.
- Such beads are commercially available i n a v ariety o f s hapes, s izes a nd m aterials, s uch a s 6 micron microspherical polystyrene beads (Polysciences, Warrington PA, USA).
- the beads can be polystyrene beads, dextran beads, glass beads or metal beads (such as 10 nm colloidal gold), preferably, the beds utilized are polystyrene beads.
- Methods of coating beads with ligand molecules, such as, for example proteins, are well known in the art. Briefly, the ligand is prepared in solution and adsorbed on a bead, such as, a polystyrene bead, which is pretreated or fabricated to include binding sites on its surface. The bead surface is thereafter contacted with a blocking solution (e.g., protein containing solution), for example, ethanolamine, gelatin BSA or powdered milk, in order to saturate the unbound binding sites of the bead.
- a blocking solution e.g., protein containing solution
- the substrate is washed with a buffered solution, the buffer is removed, and the beads are resuspended in storage buffer until use (preparation of beads, and binding of viral antigens is detailed in the Material and Methods section o f the Examples s ection which follows).
- ligand-coated beads for modeling viral infection has several advantages: (i) beads are easily detected, and their attachment is not followed by immediate internalization into the cells, hence more easily quantifiable, thus, the viral ligands and their cellular receptors are more easily identified; (ii) binding to cell surface receptors is resolved at the level of a single cell; (iii) susceptible cells, binding viral ligand-coated beads, can be easily sorted out of a heterogeneous cell population, and categorized according to relative binding capacity; (iv) high concentrations of ligand on bead surfaces can enhance binding avidity and permit detection of otherwise weak binding interactions; and (v) beads, and thus ligand-hepatocyte interactions, are easily visualized in real time.
- Coated beads have been used for analysis of adhesion mediated interactions (Levenberg, S et al J Cell Sci 1998;111 :347-357), and for detection of immune response to HBV infection (Neurath A.R et al Cell 1986;46: 429-36, and U.S. Pat. Nos. 5,620,844 and 5,204,996 to Neurath et al).
- Neurath et al disclosed solid substrates7 ⁇ such as polystyrene beads coated with hepatitis B antigens or anti-hepatitis B immunoglobulins, for detection and separation of anti-hepatitis B antibodies, or hepatitis B viral proteins from fluids, and for evaluation of anti-HBV vaccination (US Pat. No.
- the present inventors have demonstrated for the first time that beads coated with HBV sub-viral particle (SVP) proteins (Example 2), and beads coated with recombinant pre SI protein, in particular, a synthetic polypeptide representing the antigenic 21-47 amino acid epitope of the HBV preSl protein (SEQ ID NO: 1) specifically bind cultured, sensitized hepatocytes.
- SVP HBV sub-viral particle
- SEQ ID NO: 1 a synthetic polypeptide representing the antigenic 21-47 amino acid epitope of the HBV preSl protein
- binding between a ligand-coated bead and a hepatocyte can be determined by a method capable of detecting beads bound to, or internalized within the hepatocyte. Detection can be effected on the basis of visual observation, for example, microscopically or by color detection of colored beads, by the behavior of magnetically polarized beads in a magnetic field, by detection of emission, such as radioactivity or fluorescence from the beads, or by interaction with immune reactive substances bound to the beads.
- quantifying the beads binding to the hepatocyte is performed by direct microscopic observation and counting of the bound beads, according to the criteria: cells remaining unoccupied (0 beads per cell), cells attaching 1-4 beads, and cells attaching more than 4 beads each.
- Detection and quantifying of binding between viral ligand-coated beads and hepatocytes can be used to screen for substances useful in preventing viral infection.
- Putative anti-viral compounds can be added to the culture medium before, during and/or after contacting with the viral-ligand coated beads, and binding a nd/or i nternalization o f t he b eads c ompared to t hat o f c ells without added substances. Inhibition of beads binding to, or internalized into the hepatocytes would likely indicate an anti-infective effect of the substance.
- a method of identifying a substance capable of modifying viral infection in hepatocytes is effected by contacting the hepatocytes with beads coated with a viral ligand capable of binding the hepatocytes, in the presence of the substance, and then determining the amount of the beads bound to, or present in the hepatocytes, as detailed herein, to determine the infection- modifying ability of the substance.
- the viral ligand is HBsAg, and more preferably, a synthetic polypeptide representing the antigenic 21-47 amino acid epitope of the HBV preSl protein (SEQ ID NO: 1), containing the QLDPAF sequence (Example 3).
- the ligand is a synthetic peptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
- Hepatocyte -specific ligands such as asialoglycoprotein moieties (Martinez-Fong D et al Hepatology 1994;20:1602-8; van der Fluijs P et al Hepatol 1986;6:723-28), polybutylcyanoacrylate (Zhang ZR and He Q World J of Gastroentero 1999;5:330-33) and others (for review, see Wu J et al Front Biosci 2002;7:d717-25) have been associated in lipoproteins and microparticles with cell modulators such as colchicine, cytochlasin B, taxol and valaciclovir for liver-specific targeting of these drugs.
- gene therapy using recombinant, defective hepatitis B viruses, taking advantage of strict HBV hepatotropism, has been recently proposed (Wang L, et al Virus Res
- a method of delivering a substance, such as a drug, into a hepatocyte is effected by contacting the hepatocyte with a bead coated with a ligand capable of binding the hepatocyte, and the substance, thereby introducing the substance into the hepatocyte.
- coating of the bead with the substance to be delivered is performed essentially as described herein for the ligand.
- the bead can be exposed to the ligand prior to, simultaneously with, or after exposure to the ligand, prior to the blocking of available binding sites.
- the method of delivering a substance to a hepatocyte of the present invention is well suited for delivering substances, such as anti-viral drags, in vitro, to cultured hepatocytes, and in vivo, to liver cells in living organisms.
- the beads can be administered by intravenous injection or by release from a bolus introduced in or near the liver or liver blood supply.
- contacting the hepatocyte is performed in vivo.
- c ontacting the hepatocyte is performed in vitro.
- the substance to be delivered can be an antibody, a toxin, a nucleic acid or a drug.
- antibody includes intact immunoglobulin molecules as well as functional fragments thereof, such as Fab, F(ab')2, and Fv that are capable of binding to antigens.
- Fab the fragment which contains a monovalent antigen- binding fragment of an antibody molecule
- Fab' the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain
- two Fab' fragments are obtained per antibody molecule
- (Fab')2 the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction, F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds
- Fv defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains
- SCA Single chain antibody
- antibodies that can be used in the method of the present invention are anti-viral antibodies, which can be introduced into the hepatocytes to disrupt infectious processes.
- toxins refers to any of a group of poisonous substances typically active in disrupting one or more metabolic pathways of living cells. Examples of toxins commonly administered therapeutically are pertussis toxin (e.g., for gastroparesis) and botulinum toxin (bladder carcinoma).
- pertussis toxin e.g., for gastroparesis
- botulinum toxin bladedder carcinoma
- many toxins are used in cancer therapy, to weaken or kill cancerous cells. Beads coated with such toxins, and liver specific ligands, can be targeted to cancerous cells in treatment of hepatocarcinoma and other neoplasms of the liver.
- nucleic acid refers to oligo and/or polynucleotides of ribonucleic acid or deoxyribonucleic acid, or combinations thereof.
- nucleic acids that can be introduced into hepatocytes are, but are not limited to antisense or ribozyme RNA, DNA sequences encoding biologically active proteins such as receptors, enzymes and cofactors, and oligonucleotides recognizing regulatory sequences.
- the method of the present invention can be used for hepatocyte targeting in in vivo gene therapy. In in vivo gene therapy, target cells are not removed from the subject rather the genetic material to b e transferred is introduced into the cells of the recipient organism in situ, that is, within the recipient. In an alternative embodiment, if the host gene is defective, the gene is repaired in situ [Culver, 1998. (Abstract)
- drug refers to a substance used for diagnostic, cure, mitigation and/or prevention of disease.
- drags are well known in the art, including but not limited to antidepressants, barbiturates, anti- hypertensives, antacids, analgesics, antibiotics, anticonvulsants, antihistamines, steroids, antipsychotics, antidiabetics, laxatives, and the like.
- Examples of drugs specifically administered for diseases of the liver are cyclooxygenase-2 (COX 2) inhibitors such as suldinac for prevention of hepatocarcinoma, antifibrotic drags for treatment of cirrhosis, antioxidants for treatment of alcoholic hepatitis, and anti -viral drugs such as Lamividine (Example 1).
- COX 2 cyclooxygenase-2
- suldinac for prevention of hepatocarcinoma
- antifibrotic drags for treatment of cirrhosis
- antioxidants for treatment of alcoholic hepatitis
- anti -viral drugs such as Lamividine (Example 1).
- contacting the hepatocyte with ligand- and substrate-coated beads of the present invention is effected in a manner suitable for inducing endocytosis of said beads, for example, in the presence of 5-Aza-2 Deoxycytidine and a solution mediator, such as DMSO, as described herein (Example 1).
- a solution mediator such as DMSO
- composition of matter comprising a bead coated with a hepatitis viral protein and a bioactive substance, wherein the size and/or shape of the bead are selected to be suitable for undergoing endocytosis.
- the hepatitis viral proteins coated onto the beads can be HBV-HBsAg or a portion thereof, and HCV E2 envelope protein or a portion thereof.
- bioactive substance refers to a substance exhibiting a biological activity. Examples of such bioactive substances that can be used in the formulation of compositions of matter of the present invention are anti- viral and anti-cancer drugs described hereinabove.
- compositions-of-matter of the present invention can be used, for example, for investigation of effect of the bioactive substance on hepatocytes in vitro, and for therapeutic administration of the bioactive substance to hepatocytes in vivo, to subjects in need of the bioactive substance, as described in detail hereinabove.
- compositions of matter of the present invention can be administered to an individual per se or as a part of a pharmaceutical composition which includes a pharmaceutically acceptable carrier.
- a "pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
- the purpose of the pharmaceutical composition of the present invention is to facilitate administration of the bound bioactive substances to hepatocytes of an organism.
- pharmaceutically acceptable carrier refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
- An adjuvant is included under these phrases.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- Suitable routes of administration of beads may, for example, include intravenous, intramuscular, sub-cutaneous, rectal, buccal and vaginal application.
- compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
- Penetrants appropriate to the barrier to be permeated may be used in the formulation. Such penetrants are generally known in the art.
- compositions of the present invention may be formulated in rectal and vaginal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
- compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms c ontaining the active ingredient.
- a pack or dispenser device such as an FDA approved kit, which may contain one or more unit dosage forms c ontaining the active ingredient.
- the pack may be accompanied by instructions for administration.
- the pack may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
- a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
- Such notice for example, may be of labeling approved by the U.S. Food and Drug
- HepG2 and HEK 293 cells were maintained in Dulbecco's modified eagle's minimal essential medium (DMEM) (GIBCO Laboratories Grand Island New York 14072, USA) containing penicillin (lOOU/ml and Streptomycin lOO ⁇ g/ml, supplemented with 8% fetal calf seram (GIBCO Laboratories Grand Island New York 14072, USA).
- DMEM Dulbecco's modified eagle's minimal essential medium
- lOOU/ml and Streptomycin lOO ⁇ g/ml penicillin
- 8% fetal calf seram Gib Island New York 14072, USA.
- Transfections of the HEK 293 cells were carried out by the CaPi method as previously described (Haviv, I et al Mol Cell Biol 1995;15:1079-1085): Cells were seeded 8 to 12 hours prior to transfection. About 60% confluent plates were transfected with the desired plasmid
- 5-Aza-2 Deoxycytidine and DMSO Pretreatment ofHepG2 cells For 5-Aza-2 Deoxycytidine and DMSO pretreatment, HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, GIBCO Laboratories Grand Island New York USA) containing penicillin (lOOU/ml) and streptomycin (100 ⁇ g/ml) supplemented with 8% fetal calf serum (GIBCO Laboratories Grand Island New York USA). Cells (10 6 per " 10 cm dish) were seeded on glass coverslips in a 12 well plate (Corning cat #3513, Coming NY
- HBV SVPs and HCV surface proteins For production of SVPs Chinese Hamster Ovary cells (CHO) were stably transfected with the AL26 plasmid and high HBsAg producing cells were isolated. The culture medium was collected and centrifuged (Rotor SS34 17K, 30 min. at 4°C) to remove cellular debris, and the recombinant SVPs were fractionated on CsCl gradients. HBsAg level in the resulting fractions was determined by RIA using 12 T labeled polyclonal ⁇ HBsAg antibody (BTG, Rehovot, Israel).
- Soluble proteins were separated from debris and inclusion bodies by centrifugation in a SS-34 rotor (16,000g 30 min.), preincubated with lOmM Imidazole and loaded on 1ml NiNTA agarose column (Qiagene Inc, CA USA) pre-equilibrated with the equivalent buffer containing lOmM Imidazole. Non-specific proteins were removed by washing with 150 column volumes of lysis buffer containing lOmM Imidazole. The preSl proteins were step-eluted in lysis buffer containing 150mM Imidazole, and dialyzed against PBS. The identity and homogeneity of the purified proteins were determined by Coomassi staining and Western immunobloting.
- Recombinant HCV E2 protein was prepared by the baculoviras system (XTL Biopharmaceuticals Ness-Ziona Israel).
- Huh7 cells were transfected with wild type (wt) HBV DNA. At 10 days posttransfection, the culture media was collected, and viral particles were concentrated through a 30%(W/V) sucrose cushion. The pellet was re- suspended in PBS and layered on top of a preformed 20-65% (W/V) sucrose gradient (in PBS) and ultracentrifuged at 140,000g (27000 RPM) for 16 hrs at 4°C in an SW28 rotor. Fractions of 1 ml were collected from the bottom of the tube and the sucrose concentration determined by refractometer.
- the fractions were concentrated by ultracentrifugation through a 20% (W/V) sucrose cushion in PBS in SW28 rotor at 140000g (27000 RPM) for 16 hrs at 4°C, re- suspended in PBS and kept in 4 °C for further analysis.
- the HBV pellet was treated with DNase-I, reconcentrated by ultracentrifugation and resuspended in PBS.
- viral DNA was extracted from the samples by QIAamp DNA Blood Mini Kit (QIAGEN Inc, CA USA) according to the manufacturer's protocol. The DNA was then purified on a
- Antibodies and peptides Polyclonal Goat antibodies against SVPs were obtained from BTG (Bio-Technology General, Israel), diluted 1:3000 in PBS for antibody-mediated blocking assays or in PBS (0.1%)- Tween 20 + 4% dried low fat milk for Western analysis.
- the monoclonal mouse anti preSl antibody MA 18/7) (IgG 0.5mg/ml) was diluted 1 :5000 in PBS for antibody mediated blocking assays.
- the monoclonal mouse anti 6His (Sigma Israel Chemicals LTD, Rehovot, Israel) antibody was diluted 1 :3000 for Western analysis.
- Monoclonal mouse anti HBcAg antibodies were generated by injection of bacterially expressed FPLC purified HBV core particles and selection of hybridoma secreting ⁇ HBcAg antibodies.
- Polyclonal rabbit antibodies against HBV core protein were generated by repeated injection o f b acterially expressed, FPLC-purified HBV core particles.
- the ascites fluid was diluted 1:5000 in PBS.
- Western analysis horseradish peroxidase- conjugated donkey anti goat and goat anti mouse antibodies (Jackson
- a synthetic peptide comprising the 21-47 amino acids of HBV preSl PLGFFPDHQLDPAFGANSNNPDWDFNPGK (NCBI Accession No. AB056513.1, SEQ ID NO: 1) was synthesized (Weizmann Institute of Science Internal Services, Rehovot, Israel), purified by HPLC using a C18 column (Amersham Pharmacia Biotech UK LTD), lyophilized and resuspended in PBS before use. The peptide composition was confirmed by amino acid analysis (Weizmann Institute of Science internal Services, Rehovot, Israel).
- BMA Bead- Mediated Attachment
- HepG2 cells were seeded as described hereinabove, 2X10 beads were added to the cells and incubated for additional 14 hours.
- the appropriate competitor antigens were added two hours prior to the addition of the conjugated beads.
- the unbound beads were removed and cells were fixed in 4% paraformaldehyde solution and mounted in Aqua-polymount
- HBV-positive sera were used to infect cells as previously described
- HBV replicative DNA forms For analysis of HBV replicative DNA forms, infected cells were harvested at the indicated time intervals and total and extrachromosomal DNA extracted and analyzed by agarose gel electrophoresis and Southern blotting (Tuttleman, J.S. et al J Virol 1986; 58: 17-25). HBV sequences were detected using P labeled DNA probes synthesized by random priming from an intact HBV DNA genome template.
- MRC-1024 confocal system utilizing an Argon/Krypton mixed gas laser and mounted on a Zeiss Axiovert microscope.
- SEM Scanning electron microscopy
- Sections were prepared using a diamond knife (Diatome, Biel) and examined using a Philips CM- 12 transmission electron microscope- at an accelerating voltage of lOOKV SVP were visualized by negative staining (Weizmann Institute Internal Services, Rehovot Israel).
- HBV infection of cultured human hepatic cells is a primary requirement for effective investigation of virus-cell interactions, and prevention and treatment of the disease.
- established human hepatocyte lines such as HepG2 and Huh-7 are refractive to HBV infection.
- treatment with 1.5-2% DMSO results in enhanced and prolonged HBV (Gripon, P et al J Virol 1988;62:4136-4143) and DHBV infection (Pugh, J.C. and Summers, J.W. Virology 1989; 172:564-572).
- the replicative intermediate DNA forms could not be detected in cells treated with Lamivudine (3TC), a potent HBV RTase inhibitor (Fig IC, lane 8), indicating that viral DNA replication is the result of reverse- transcriptase activity.
- Lamivudine 3TC
- Fig IC potent HBV RTase inhibitor
- a neutralizing antibody raised against the 21-47 amino acids region of preSl MA 18/7)
- Nerath, A.R. et al Vaccine 1989;7: 234-236 effectively blocked infection in the DMSO-treated HepG2 cells as well (Fig IC lane 9).
- Hep G2 cells pretreated by DMSO efficiently support both HBV infection and replication, mimicking natural infection.
- Example 2 DMSO-treated HepG2 cells bind recombinant viral protein-conjugated beads Preparation of HBV sub-viral particles (SVP) for Bead-Mediated Attachment (BMA) Assay Due to the paucity of pertinent experimental data, the underlying mechanisms of HBV infection of cultured hepatocytes cell lines have remained unclear. In order to elucidate the nature and action of the involved receptors [specifically, whether the DMSO-mediated enhancement of infection requires induced expression and presentation of differentiation-specific viral receptors (receptor activation)] and provide a quantitative measure of virus attachment, the bead-mediated attachment (BMA) assay that measures viral attachment at single cell resolution was developed.
- SVP sub-viral particles
- BMA Bead-Mediated Attachment
- HBV sub- viral particles were p roduced i n a nimal cells by utilizing the AL26 plasmid that contains an integrated form of HBV DNA (Faktor, O et al Virology 1988;162:362-368).
- Chinese Hamster Ovary (CHO) cells were transfected with AL26 plasmid and h igh H BsAg p roducer lines were established that secrete HBsAg sub-viral particles (SVPs) with the expected 1.22 gr/ml density ( Figure 2A). Electron microscopy revealed that the particles are spherical and homogeneous in size (22nm in diameter).
- HBV viral antigen- coated beads can mimic mechanisms of viral-hepatic cell interactions
- recombinant SVP containing all three HBsAg components were conjugated to synthetic beads, as described in the Methods section hereinabove, to obtain SVP-beads.
- Control BSA-conjugated beads were also prepared and both were incubated for 16 hrs with untreated HepG2 cells. The unbound beads were removed, the cells fixed and the number of the attached beads per cell was determined by light microscopy. The percentage of the cells that bind SVP- beads (50%) was significantly higher than the control BSA-beads (18.7%) ( Figure 3A, 3B).
- pretreatment with DMSO significantly improved SVP-beads attachment, with nearly all (93%) of the treated cells binding beads, as compared to 50% of untreated cells ( Figures 3C and 3D).
- about 49% of the treated cells bind more than 4 SVP-beads per cell ( Figure 3D), 244 fold higher than the binding in untreated cells (0.2%, Figure 3B).
- the DMSO-mediated enhancement in SVP-beads attachment is specific, as the majority (56%) of the cells bind no BSA-beads at all and only 0.8% bind more than 4 beads per cell.
- preSl protein was prepared and conjugated to beads (preSl -beads). This region of the large HBsAg protein was previously shown to play an important role in receptor recognition (De Meyer, S et al J Viral Hepat 1997;4:145-153; Le
- HepG2 cells can be made even more susceptible to HBV infection by addition of 5 '-Aza-2 '-Deoxycytidine to DMSO.
- treatment of the cells with 2% DMSO+100 mM 5 '-Aza-2'- Deoxycytidine resulted in a two-foH increase in HBV " preSl -attachment to HepG2 cells over that attained with DMSO treatment alone.
- HBV pX can also be immunoprecipitated by the MA 18/7 anti preSl antibody (unpublished data), indicating that pX might also be involved in cell attachment.
- MA 18/7 anti preSl antibody unpublished data
- pX might also be involved in cell attachment.
- two HepG2 EGF-repeat proteins that bind recombinant preSl, and are induced by DMSO one has been reported to bind pX (Sun BS et al, Hepatology 1998;27:228-39).
- a search of the protein sequence database revealed that this minimal epitope is shared by other viral, bacterial and cellular proteins that participate in cell adhesion, attachment and fusion ( Figure 6D).
- the BMA assay successfully identified the QLDPAF sequence, or a portion thereof, as a general motif critical to ⁇ BV adherence and attachment to hepatic cells in HBV infection.
- Example 4 BMA analysis of small HBsAg reveals a secondai ⁇ non-preSl attachment region and multivalent interaction in HepG2 binding
- HBV sub-viral, particles were prepared, composed of the small HBsAg and lacking the preSl and preS2 regions ( Figure 7A, sSVP,).
- Figure 7A the non- preSl and non preS2 beads display specific attachment in a DMSO-dependent manner ( Figure 7B).
- binding efficiency of the sSVP-beads was about 5 times lower (7.9% vs. 48.8%) than that obtained with SVP beads bearing the preSl domain (SVP+, Figure 7B).
- BMA assay it was revealed that small HBsAg has an additional and independent attachment site that interacts with a distinct cellular receptor.
- treatnienf of cultured hepatic cells with DMSO renders them susceptible to active infection with HBV, and binding-internalization of recombinant viral protein-conjugated beads, providing, for the first time, a hepatic cell culture system for in vitro infection with HBV and other viruses, an efficient attachment assay for diagnostic, clinical and research applications, and novel methods for delivery of various substances to cells. Furthermore, using the methods of the present invention, the importance of the QLPD epitope to cell-virus, virus-virus and cell-cell interactions was uncovered.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002324307A AU2002324307A1 (en) | 2001-07-31 | 2002-07-31 | Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30858201P | 2001-07-31 | 2001-07-31 | |
US60/308,582 | 2001-07-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003011209A2 true WO2003011209A2 (en) | 2003-02-13 |
WO2003011209A3 WO2003011209A3 (en) | 2004-07-29 |
WO2003011209A8 WO2003011209A8 (en) | 2004-09-23 |
Family
ID=23194545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2002/000628 WO2003011209A2 (en) | 2001-07-31 | 2002-07-31 | Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002324307A1 (en) |
WO (1) | WO2003011209A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135464B2 (en) | 2002-06-05 | 2006-11-14 | Supergen, Inc. | Method of administering decitabine |
WO2008095438A1 (en) * | 2007-02-02 | 2008-08-14 | Peking University People's Hospital | Utilizing liver cell line qsg-7701 to be infected with hepatitis b virus |
US8828940B2 (en) | 2006-09-18 | 2014-09-09 | Compugen Ltd. | Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands |
WO2016174130A1 (en) * | 2015-04-28 | 2016-11-03 | Université De Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
WO2017070145A1 (en) * | 2015-10-19 | 2017-04-27 | Cellular Dynamics International, Inc. | Production of virus-receptive pluripotent stem cell (psc)-derived hepatocytes |
US9969979B2 (en) | 2012-08-31 | 2018-05-15 | The Governors Of The University Of Alberta | Methods for producing cells having a phenotype of a primary human hepatocytes and compositions |
-
2002
- 2002-07-31 AU AU2002324307A patent/AU2002324307A1/en not_active Abandoned
- 2002-07-31 WO PCT/IL2002/000628 patent/WO2003011209A2/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
GRIPON P.: 'Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration' VIROLOGY vol. 192, September 1993, pages 534 - 540, XP000999341 * |
PUGH J.C.: 'Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo' J. VIROL. vol. 68, no. 4, April 1994, pages 2487 - 2494, XP002978145 * |
RUMIN S.: 'Long-term productive episomal hepatitis B virus replication in primary cultures of adult human hepatocytes infected in vitro' J. VIRL. HEPATITIS vol. 3, May 1996, pages 227 - 238, XP002978187 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135464B2 (en) | 2002-06-05 | 2006-11-14 | Supergen, Inc. | Method of administering decitabine |
US7144873B2 (en) | 2002-06-05 | 2006-12-05 | Supergen, Inc. | Kit for delivering decitabine in vivo |
US8828940B2 (en) | 2006-09-18 | 2014-09-09 | Compugen Ltd. | Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands |
EP2752423A3 (en) * | 2006-09-18 | 2015-02-18 | Compugen Ltd. | GPCR ligands and method of using same |
WO2008095438A1 (en) * | 2007-02-02 | 2008-08-14 | Peking University People's Hospital | Utilizing liver cell line qsg-7701 to be infected with hepatitis b virus |
CN100497603C (en) * | 2007-02-02 | 2009-06-10 | 北京大学人民医院 | Use of liver cell line QSG-7701 for infecting hepatitis B virus |
US8124409B2 (en) | 2007-02-02 | 2012-02-28 | Peking University People's Hospital | Utilizing liver cell line QSG-7701 to be infected with hepatitis B virus |
US9969979B2 (en) | 2012-08-31 | 2018-05-15 | The Governors Of The University Of Alberta | Methods for producing cells having a phenotype of a primary human hepatocytes and compositions |
WO2016174130A1 (en) * | 2015-04-28 | 2016-11-03 | Université De Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
WO2017070145A1 (en) * | 2015-10-19 | 2017-04-27 | Cellular Dynamics International, Inc. | Production of virus-receptive pluripotent stem cell (psc)-derived hepatocytes |
US10093903B2 (en) | 2015-10-19 | 2018-10-09 | FUJIFILM Cellular Dynamics, Inc. | Production of virus-receptive pluripotent stem cell (PSC)-derived hepatocytes |
Also Published As
Publication number | Publication date |
---|---|
WO2003011209A3 (en) | 2004-07-29 |
AU2002324307A1 (en) | 2003-02-17 |
WO2003011209A8 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Paran et al. | HBV infection of cell culture: evidence for multivalent and cooperative attachment | |
JP2810032B2 (en) | NANBV diagnostics | |
Schulze et al. | Hepatocyte polarization is essential for the productive entry of the hepatitis B virus | |
Chai et al. | Properties of subviral particles of hepatitis B virus | |
Cooper et al. | The earliest steps in hepatitis B virus infection | |
JP3645904B2 (en) | Method for classification of hepatitis C virus type and reagent used therefor | |
Budkowska et al. | Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain | |
JPH07503614A (en) | Mammalian expression system for HCV proteins | |
Lu et al. | Study of the early steps of the Hepatitis B Virus life cycle | |
Favorov et al. | Enzyme immunoassay for the detection of antibody to hepatitis E virus based on synthetic peptides | |
Falcón et al. | Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected patients | |
JP2022031634A (en) | Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus | |
Dienes et al. | Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B | |
Lai et al. | IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenetic role of HBsAG | |
Xiang et al. | Recombinant hepatitis C virus‐like particles expressed by baculovirus: utility in cell‐binding and antibody detection assays | |
JPH11506328A (en) | Diagnosis of positive-strand RNA viruses using isolated, unprocessed polypeptides and vaccination against positive-strand RNA viruses | |
WO2003011209A2 (en) | Methods of sensitizing hepatocyte cell cultures to hepatitis infection, beads coated with hbv or hcv polypeptides and methods of using such beads to model viral infection or deliver substances into hepatocytes | |
WO1993006488A1 (en) | Peptide based hepatitis c virus immunoassays | |
JPH09117287A (en) | Gb type hepatitis virus recombination protein and its use | |
Yamada et al. | Immunoelectron microscopic observation of intrahepatic HBeAg in patients with chronic hepatitis B | |
Feitelson et al. | Characteristics of woodchuck hepatitis X-antigen in the livers and sera from infected animals | |
JPH0940694A (en) | Synthetic peptide of hepatitis gb virus and its use | |
Jin et al. | Protease-activated lymphoid cell and hepatocyte recognition site in the preS1 domain of the large woodchuck hepatitis virus envelope protein | |
JP2000514643A (en) | Antigenic epitope of a-determinant of hepatitis B surface antigen and its use | |
JP2012047543A (en) | Autoantibody detection method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WR | Later publication of a revised version of an international search report | ||
122 | Ep: pct application non-entry in european phase | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |